CO2017009954A2 - Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina - Google Patents
Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúminaInfo
- Publication number
- CO2017009954A2 CO2017009954A2 CONC2017/0009954A CO2017009954A CO2017009954A2 CO 2017009954 A2 CO2017009954 A2 CO 2017009954A2 CO 2017009954 A CO2017009954 A CO 2017009954A CO 2017009954 A2 CO2017009954 A2 CO 2017009954A2
- Authority
- CO
- Colombia
- Prior art keywords
- repeats
- designed
- binding specificity
- ankyrine
- domains
- Prior art date
Links
- 102000007562 Serum Albumin Human genes 0.000 title abstract 2
- 108010071390 Serum Albumin Proteins 0.000 title abstract 2
- 102000023732 binding proteins Human genes 0.000 abstract 5
- 108091008324 binding proteins Proteins 0.000 abstract 5
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 abstract 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 abstract 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
Abstract
Se describen nuevos dominios diseñados con repeticiones de anquirina con especificidad de unión para seroalbúmina, proteínas de unión recombinantes que comprenden al menos dos dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina, así como proteínas de unión recombinantes que comprenden al menos un dominio diseñado con repeticiones de anquirina con especificidad de unión para el factor de crecimiento del hepatocito (HGF), al menos un dominio diseñado con repeticiones de anquirina con especificidad de unión para el factor de crecimiento endotelial vascular (VEGF-A) y al menos dos dominios diseñados con repeticiones de anquirina con especificidad de unión para seroalbúmina, así como ácidos nucleicos que codifican dichos dominios diseñados con repeticiones de anquirina y proteínas de unión recombinantes, composiciones farmacéuticas que comprenden dichos dominios diseñados con repeticiones de anquirina, proteínas de unión recombinantes o ácidos nucleicos y el uso de dichos dominios diseñados con repeticiones de anquirina, proteínas de unión recombinantes, ácidos nucleicos o composiciones farmacéuticas en el tratamiento de enfermedades.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15162511 | 2015-04-02 | ||
EP15162502 | 2015-04-02 | ||
PCT/EP2016/057272 WO2016156596A1 (en) | 2015-04-02 | 2016-04-01 | Designed ankyrin repeat domains with binding specificity for serum albumin |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2017009954A2 true CO2017009954A2 (es) | 2018-02-20 |
Family
ID=55650423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2017/0009954A CO2017009954A2 (es) | 2015-04-02 | 2017-09-29 | Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina |
Country Status (21)
Country | Link |
---|---|
US (3) | US9458211B1 (es) |
EP (2) | EP4272838A3 (es) |
JP (1) | JP6552636B2 (es) |
KR (2) | KR102427117B1 (es) |
CN (1) | CN107454904A (es) |
AU (3) | AU2016240220B2 (es) |
BR (1) | BR112017020986A2 (es) |
CA (1) | CA2979602C (es) |
CL (1) | CL2017002454A1 (es) |
CO (1) | CO2017009954A2 (es) |
ES (1) | ES2953482T3 (es) |
HK (1) | HK1244009A1 (es) |
IL (2) | IL276944B (es) |
MX (2) | MX2022008302A (es) |
MY (1) | MY179505A (es) |
NZ (1) | NZ735803A (es) |
PH (1) | PH12017501792A1 (es) |
RU (1) | RU2769470C2 (es) |
SA (1) | SA517390092B1 (es) |
SG (1) | SG11201707606RA (es) |
WO (1) | WO2016156596A1 (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2008012991A (es) | 2006-04-07 | 2008-10-17 | Procter & Gamble | Anticuerpos que ligan proteina tirosina fosfatasa humana beta (hptpbeta) y los usos de estos. |
KR20140032356A (ko) * | 2010-11-26 | 2014-03-14 | 몰리큘라 파트너스 아게 | 설계된 안키린 반복 단백질에 대한 개선된 n-말단 캡핑 모듈 |
AU2017299581B2 (en) | 2016-07-20 | 2024-05-23 | EyePoint Pharmaceuticals, Inc. | Humanized monoclonal antibodies that target ve-ptp (hptp-β) |
BR112019005587A2 (pt) | 2016-09-22 | 2019-06-11 | Molecular Partners Ag | proteínas de ligação recombinantes e sua utilização |
WO2019011167A1 (zh) * | 2017-07-12 | 2019-01-17 | 四川科伦博泰生物医药股份有限公司 | 双特异性重组蛋白 |
JP2021500851A (ja) * | 2017-08-18 | 2021-01-14 | ケンブリッジ・エンタープライズ・リミテッドCambridge Enterprise Limited | モジュラー結合タンパク質 |
WO2020068653A1 (en) | 2018-09-24 | 2020-04-02 | Aerpio Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF |
KR20220044612A (ko) * | 2019-03-22 | 2022-04-08 | 리플렉시온 파마슈티컬스, 인크. | Vegf에 대한 d-펩티드성 화합물 |
KR20220016942A (ko) | 2019-06-04 | 2022-02-10 | 몰리큘라 파트너스 아게 | 재조합 fap 결합 단백질 및 이의 용도 |
US20220298212A1 (en) | 2019-06-04 | 2022-09-22 | Molecular Partners Ag | Recombinant 4-1bb binding proteins and their use |
CN114206943A (zh) * | 2019-06-04 | 2022-03-18 | 分子伴侣公司 | 多特异性蛋白质 |
BR112021024237A2 (pt) | 2019-06-04 | 2022-04-19 | Molecular Partners Ag | Domínio de repetição de anquirina projetado com estabilidade aprimorada |
CN115003689A (zh) | 2019-12-11 | 2022-09-02 | 分子合作伙伴股份公司 | 具有改变的表面残基的经设计的锚蛋白重复结构域 |
JP2023506763A (ja) | 2019-12-11 | 2023-02-20 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 組換えペプチド-mhc複合体結合タンパク質並びにそれらの生成及び使用 |
JP2023525518A (ja) | 2020-05-06 | 2023-06-16 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 新規アンキリンリピート結合タンパク質とその用途 |
IL298168A (en) | 2020-05-14 | 2023-01-01 | Molecular Partners Ag | Multispecific proteins |
AU2021271131A1 (en) | 2020-05-14 | 2022-12-15 | Molecular Partners Ag | Recombinant CD40 binding proteins and their use |
EP3957649A1 (en) | 2020-08-18 | 2022-02-23 | Athebio AG | Improved n-terminal capping modules of ankyrin repeat domains |
CA3202296A1 (en) * | 2020-12-16 | 2022-06-23 | Sebastian Grimm | Recombinant cd3 binding proteins and their use |
WO2022130300A1 (en) * | 2020-12-16 | 2022-06-23 | Molecular Partners Ag | Novel slow-release prodrugs |
CA3211248A1 (en) | 2021-03-09 | 2022-09-15 | Nina RESCHKE | Novel darpin based cd33 engagers |
BR112023018293A2 (pt) | 2021-03-09 | 2023-10-31 | Molecular Partners Ag | Acopladores de célula t multiespecíficos à base de darpin |
WO2022190018A1 (en) | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Novel darpin based cd123 engagers |
WO2022190008A1 (en) | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Protease cleavable prodrugs |
WO2023110983A1 (en) | 2021-12-14 | 2023-06-22 | Molecular Partners Ag | Designed repeat domains with dual binding specificity and their use |
CN114957426B (zh) * | 2022-06-02 | 2023-05-16 | 华南师范大学 | Sp6rars及其在防治蜚蠊目昆虫中的应用 |
US20240132546A1 (en) | 2022-07-31 | 2024-04-25 | Molecular Partners Ag | Charge modified designed repeat domains and their use |
WO2024038307A1 (en) | 2022-08-19 | 2024-02-22 | Novartis Ag | Dosing regimens for sars-cov-2 binding molecules |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
DE60140474D1 (de) | 2000-09-08 | 2009-12-24 | Univ Zuerich | Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
BRPI0517834A (pt) | 2004-11-12 | 2008-10-21 | Bayer Schering Pharma Ag | vìrus da doença de newcastle recombinante |
PL1888641T3 (pl) | 2005-05-18 | 2012-05-31 | Ablynx Nv | Białka wiążące albuminę surowicy |
RU2412249C2 (ru) | 2005-07-08 | 2011-02-20 | Юниверсити Оф Цюрих | Фаговый дисплей с применением котрансляционной транслокации слитых полипептидов |
EP1996220B2 (en) | 2006-03-06 | 2023-08-16 | Amunix Operating Inc. | Unstructured recombinant polymers and uses thereof |
EA021222B8 (ru) | 2007-06-21 | 2015-11-30 | ИксЭль-ПРОТЕИН ГМБХ | Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro |
JP2010539915A (ja) | 2007-09-24 | 2010-12-24 | ユニバーシティ・オブ・チューリッヒ | 設計されたアルマジロリピートタンパク質 |
CA2742241C (en) | 2008-11-03 | 2019-12-10 | Molecular Partners Ag | Binding proteins inhibiting the vegf-a receptor interaction |
EP2531523A1 (en) | 2010-02-05 | 2012-12-12 | Ablynx N.V. | Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same |
AR081361A1 (es) | 2010-04-30 | 2012-08-29 | Molecular Partners Ag | Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a |
EP2933262B1 (en) * | 2010-07-09 | 2018-05-02 | Affibody AB | Polypeptides |
WO2012010548A1 (en) * | 2010-07-19 | 2012-01-26 | F. Hoffmann-La Roche Ag | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
WO2012069557A1 (en) * | 2010-11-24 | 2012-05-31 | Glaxo Group Limited | Multispecific antigen binding proteins targeting hgf |
KR20140032356A (ko) | 2010-11-26 | 2014-03-14 | 몰리큘라 파트너스 아게 | 설계된 안키린 반복 단백질에 대한 개선된 n-말단 캡핑 모듈 |
BR112013027766A2 (pt) | 2011-04-29 | 2016-11-29 | Janssen Biotech Inc | proteinas de repetição de ligação de il4/il13 e usos |
SG11201408196RA (en) | 2012-06-28 | 2015-03-30 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
EP2738180A1 (en) * | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
EP3004152B1 (en) * | 2013-05-31 | 2020-09-30 | Molecular Partners AG | Designed ankyrin repeat proteins binding to hepatocyte growth factor |
-
2016
- 2016-04-01 EP EP23177745.9A patent/EP4272838A3/en active Pending
- 2016-04-01 BR BR112017020986-1A patent/BR112017020986A2/pt active Search and Examination
- 2016-04-01 ES ES16713904T patent/ES2953482T3/es active Active
- 2016-04-01 EP EP16713904.7A patent/EP3277711B9/en active Active
- 2016-04-01 WO PCT/EP2016/057272 patent/WO2016156596A1/en active Application Filing
- 2016-04-01 CN CN201680019907.XA patent/CN107454904A/zh active Pending
- 2016-04-01 MY MYPI2017703637A patent/MY179505A/en unknown
- 2016-04-01 CA CA2979602A patent/CA2979602C/en active Active
- 2016-04-01 JP JP2017551176A patent/JP6552636B2/ja active Active
- 2016-04-01 MX MX2022008302A patent/MX2022008302A/es unknown
- 2016-04-01 SG SG11201707606RA patent/SG11201707606RA/en unknown
- 2016-04-01 MX MX2017012485A patent/MX2017012485A/es unknown
- 2016-04-01 KR KR1020177030096A patent/KR102427117B1/ko active IP Right Grant
- 2016-04-01 KR KR1020227025940A patent/KR20220109488A/ko not_active Application Discontinuation
- 2016-04-01 IL IL276944A patent/IL276944B/en unknown
- 2016-04-01 RU RU2017134456A patent/RU2769470C2/ru active
- 2016-04-01 AU AU2016240220A patent/AU2016240220B2/en active Active
- 2016-04-01 NZ NZ735803A patent/NZ735803A/en unknown
- 2016-04-01 US US15/089,014 patent/US9458211B1/en active Active
- 2016-08-26 US US15/248,731 patent/US10155791B2/en active Active
-
2017
- 2017-09-28 PH PH12017501792A patent/PH12017501792A1/en unknown
- 2017-09-28 CL CL2017002454A patent/CL2017002454A1/es unknown
- 2017-09-28 IL IL254788A patent/IL254788B/en active IP Right Grant
- 2017-09-29 CO CONC2017/0009954A patent/CO2017009954A2/es unknown
- 2017-10-02 SA SA517390092A patent/SA517390092B1/ar unknown
-
2018
- 2018-03-12 HK HK18103392.8A patent/HK1244009A1/zh unknown
- 2018-11-02 US US16/178,923 patent/US11332501B2/en active Active
-
2020
- 2020-02-21 AU AU2020201264A patent/AU2020201264A1/en not_active Abandoned
-
2021
- 2021-12-17 AU AU2021286418A patent/AU2021286418B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2017009954A2 (es) | Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina | |
CO2019002609A2 (es) | Proteínas de unión recombinantes y sus usos | |
UY35407A (es) | ?PROTEÍNAS DE FUSIÓN COMPRENDIENDO PORCIONES PDGF y VEGF DE UNIÓN Y MÉTODOS PARA SU USO?. | |
BR112018068189A2 (pt) | proteínas de ligação induzíveis e métodos de uso | |
GEP20227447B (en) | Constructs having sirp-alpha domain or variant thereof | |
CY1124106T1 (el) | Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων | |
EA201892691A1 (ru) | Однодоменный белок, связывающий сывороточный альбумин | |
BR112017010088A2 (pt) | polinucleotídeo modulatório, pré-micro-rna artificial, vírus recombinante de aav, composição compreendendo o plasmídeo ou vetor, kit compreendendo o referido plasmídeo ou vetor e uso do mesmo | |
BR112019001737A2 (pt) | expressão de pten-long com vírus oncolíticos | |
EA201491644A1 (ru) | Фармацевтические композиции | |
EA201791168A1 (ru) | Способы и составы для лечения сосудистых заболеваний глаз | |
BR112017024899A2 (pt) | proteínas de ligação trispecíficas e métodos de uso. | |
BR112017014615A2 (pt) | proteínas de fusão de multi-direcionamento e seus usos | |
BR112016016916A8 (pt) | uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae) | |
EA201890320A1 (ru) | Молекулы антител, которые связывают cd79 | |
EA201792466A1 (ru) | АНТИТЕЛА ПРОТИВ FcRn | |
EA202191513A1 (ru) | Снижение вязкости фармацевтических составов | |
CO2020000369A2 (es) | Polipéptidos que se unen al componente del complemento c5 o albumina sérica y proteínas de fusión de los mismos | |
BR112019010128A2 (pt) | proteínas de ligação a antígeno anti-gitr e métodos de uso das mesmas | |
CO2017011583A2 (es) | Polipéptidos dirigidos a la fusión de vih | |
MX2021014649A (es) | Dominio de repetición de anquirina diseñado con estabilidad mejorada. | |
TW201713686A (en) | Methods for preparing modified von Willebrand factor | |
DK3399040T3 (da) | Fremgangsmåde til fremstilling af porcine circovirus type 2 capsid-protein og farmaceutisk sammensætning omfattende samme | |
BR112017000710A2 (pt) | polipeptídeo isolado, polipeptídeo modificado de revestimento final isolado, composição de matéria, polipeptídeo de fusão isolado, composição farmacêutica, método de tratamento de uma doença inflamatória, uso do polipeptídeo isolado, polinucleotídeo isolado, estrutura de ácido nucleico, e método de determinação da potência de um lote do polipeptídeo isolado | |
BR112016002570A2 (pt) | alvos moleculares para o tratamento de feridas, em particular, feridas crônicas |